Eli Lilly and Company (NYSE:LLY) Shares Sold by High Note Wealth LLC

High Note Wealth LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 0.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,987 shares of the company’s stock after selling 34 shares during the period. High Note Wealth LLC’s holdings in Eli Lilly and Company were worth $2,324,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. S.A. Mason LLC lifted its position in shares of Eli Lilly and Company by 2.0% during the 4th quarter. S.A. Mason LLC now owns 1,786 shares of the company’s stock worth $1,041,000 after purchasing an additional 35 shares during the last quarter. Highland Capital Management LLC raised its stake in Eli Lilly and Company by 2.8% during the 4th quarter. Highland Capital Management LLC now owns 13,350 shares of the company’s stock worth $7,782,000 after acquiring an additional 360 shares in the last quarter. Columbia Trust Co 01012016 raised its stake in Eli Lilly and Company by 3.8% during the 4th quarter. Columbia Trust Co 01012016 now owns 1,056 shares of the company’s stock worth $616,000 after acquiring an additional 39 shares in the last quarter. Cresta Advisors Ltd. acquired a new stake in Eli Lilly and Company during the 4th quarter worth $295,000. Finally, jvl associates llc raised its stake in Eli Lilly and Company by 44.1% during the 4th quarter. jvl associates llc now owns 588 shares of the company’s stock worth $343,000 after acquiring an additional 180 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent research reports. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Bank of America boosted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research note on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $689.52.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 14,388 shares of Eli Lilly and Company stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $630.28, for a total value of $9,068,468.64. Following the transaction, the insider now owns 99,754,422 shares in the company, valued at $62,873,217,098.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have sold 195,055 shares of company stock worth $125,254,657. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $778.69 on Thursday. The company has a market cap of $739.88 billion, a P/E ratio of 134.26, a P/E/G ratio of 1.70 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $334.58 and a 52 week high of $800.78. The business has a fifty day simple moving average of $727.96 and a 200-day simple moving average of $636.01.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.09 earnings per share. Equities research analysts forecast that Eli Lilly and Company will post 12.42 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.